We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Great Basin Welcomes Kirk Calhoun to Board of Directors Mr. Calhoun Will Serve as Head of the Audit Committee PR Newswire SALT LAKE CITY, June 2, 2015 SALT LAKE CITY, June 2, 2015 /PRNewswire/...
LOS ANGELES, May 14, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, May 7, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, March 19, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, Jan. 15, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
LOS ANGELES, June 16, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help guide cancer therapy...
LOS ANGELES, June 12, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help guide cancer therapy...
LOS ANGELES, May 14, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help guide cancer therapy...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 750 | 1.0E-6 | CS |
26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 300 | 1.0E-6 | CS |
52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 250 | 1.0E-6 | CS |
156 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 4937 | 3.75E-6 | CS |
260 | -0.004049 | -99.975308642 | 0.00405 | 0.0446 | 1.0E-6 | 121994 | 0.00566621 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions